Cétirizine topique 1 %

cetirizine and minoxidil groups, the p- value based on the number of terminal follicle hairs and vellus hairs was greater than 0.05, indi- cating no significant difference between the cetirizine and minox- idil groups (Figure 1).

Seifian H, Safari Giv T, Abdollahimajd F et al.. Topical cetirizine for the management of androgenic alopecia: results of a pilot study. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.15989. Citation sous licence CC-BY.

cetirizine and minoxidil groups, the p- value based on the number of terminal follicle hairs and vellus hairs was greater than 0.05, indi- cating no significant difference between the cetirizine and minox- idil groups (Figure 1).

Seifian H, Safari Giv T, Abdollahimajd F et al.. Topical cetirizine for the management of androgenic alopecia: results of a pilot study. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.15989. Citation sous licence CC-BY.

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

(Figures 2A, 2B and 3). Based on physicians’ opinions, after 16 weeks of treatment in the cetirizine group, hair density in 33% of participants slightly increased, 50% of participants did not differ in hair 193 J Pharm Pharm Sci (www.cspsCanada.org) 24, 191 - 199, 2021 density and in 17% of the subjects hair density slightly decreased. Whereas in the minoxidil group, 25% had a slight increase in hair density and in 75% of participants no changes from baseline were detectable (Figure 2A). In the cetirizine group, after 8 weeks of using the placebo solution, by comparing weeks 16 and 24, hair density in 25% of participants slightly increased, 41% experienced no difference in their hair density Figure 1. Changes in Biometric Indices of Hair along 24 Weeks of Study in Both Groups Cetirizine, Minoxidil. A) Total hair density, B) vellus hair density, C) terminal hair density, D) Percentage of hair in anagen phase, E) Percentage of hair in telogen

Hossein Mostafa D, Samadi A, Niknam S et al.. Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. Journal of Pharmacy and Pharmaceutical Sciences 2021. Citation sous licence CC-BY-SA.

Photographic assessment of the control group revealed no im- provement among all subjects, while only 17 (56.7%) of the cases demonstrated no improvement. Mild improvement was observed in 10 (33.3%) of the cases, while good improvement was observed in 2 (6.7%) of the cases. The difference in observed improvement among both groups was statistically significant (P < .001) (Table 3).

Zaky MS, Abo Khodeir H, Ahmed HA et al.. Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: a case-controlled study. Journal of Cosmetic Dermatology 2021, DOI 10.1111/jocd.13940. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In the minoxidil group, the average of Sinclair and shedding indices were 2.92 ± 0.81 and 4.27 ± 1.24 at the baseline, which was significantly decreased to 2.33 ± 0.90 and 3.20 ± 1.25 after 3 months (p-value of 0.076 and 0.026, respectively). In the cetirizine group, significant improvement was observed in the shedding scale. At the baseline, the average of Sinclair and shedding indices were 2.73 ± 0.75 and 4.18 ± 0.92, respectively, which decreased to 2.59 ± 0.90 and 3.71 ± 0.96 after 3 months (p-value of 0.185 and 0.032, respectively). According to ITT analysis, the two groups were not sig- nificantly different after 3 months of therapy, based on Sinclair and shedding scales (p value of 0.221 and 0.161, respectively).

Alavi SMK, Layegh P, Vahabi-Amlashi S et al.. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial.. Expert Rev Clin Pharmacol 2023, DOI 10.1080/17512433.2023.2243813. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Mild Pruritus (15%) and scaling (10%) were the main complaints in the minoxidil group, whereas no side effects were seen in the cetirizine group.

Hossein Mostafa D, Samadi A, Niknam S et al.. Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. Journal of Pharmacy and Pharmaceutical Sciences 2021. Citation sous licence CC-BY-SA.